The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Meg Rivers is the former senior editor for 

Articles

Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.

The Real Danger of Substandard and Counterfeit COVID-19 Vaccines

The COVID-19 pandemic has further impacted ongoing drug shortage issues; essential action is needed to avoid repeating previous mistakes.

Changing the Course of Drug Shortages

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.

Biden Bolsters Vaccine Production in Pandemic Preparedness Plan

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Alternative materials, as well as supply-chain planning, are essential to ensure a reliable supply for parenteral drug packaging.

Setting a Clear Strategy for Primary Packaging

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Getting a Nose for Vaccines

Merlin Piscitelli is the chief revenue officer for EMEA at Datasite. Datasite is a leading SaaS provider for the M&A industry, giving dealmakers the tools and insights they need to succeed across the entire deal lifecycle.

Despite the market challenges caused by COVID-19, M&A activity in the life sciences sector is recovering well.

Looking Ahead to Factors Shaping Market Activity

SK and GSK announce the initiation of a Phase III clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant.

SK Bioscience and GSK Start Phase III Trial of Adjuvanted COVID-19 Vaccine Candidate

Merck and Ridgeback Biotherapeutics announced the initiation of the Phase III clinical trial to evaluate an investigational oral antiviral therapeutic for the prevention of COVID-19 infection.

Merck and Ridgeback Biotherapeutics Initiate Phase III Trial to Evaluate Molnupiravir for COVID-19

Two of FDA’s vaccine regulators will be leaving in the fall of 2021, which has the potential to impact COVID-19 vaccine recommendations for both children under the age of 12 and booster shots.

What Does the Retirement of Two Senior FDA Officials Mean for COVID-19 Vaccine Regulations?

After receiving the COVID-19 vaccine from a batch of Moderna vaccines that were suspected to have contaminants, two people in Japan died. Meanwhile, another one million doses have been temporarily suspended in Japan.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success